BORZOMED Injection 2mg

Borzomed 2mg Injection is a chemotherapy drug classified as a proteasome inhibitor. Its active component is Bortezomib. This medication is prescribed for treating multiple myeloma and mantle cell lymphoma. Multiple myeloma is characterized by the malignant growth of plasma cells in the bone marrow, while mantle cell lymphoma is a rarer form of cancer that impacts the lymph nodes. Borzomed is often administered alongside other chemotherapy agents such as pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone, or thalidomide for patients who have not yet begun treatment and are not candidates for blood stem cell transplantation.

Common side effects associated with Borzomed 2mg Injection include pneumonia, decreased appetite, skin sensitivity, tingling and burning sensations, nausea, vomiting, diarrhea, mouth sores, constipation, muscle and bone discomfort, hair loss, fever, infections, itching, redness, dehydration, and gastrointestinal issues. If these side effects are bothersome or persist, please inform your physician.

Notify your doctor if you have an allergy to Borzomed 2mg Injection or any of its components. This medication should not be used if you have serious lung or heart conditions. Prior to initiating treatment, inform your physician if you have neuropathy (nerve dysfunction), heart issues, severe lung conditions, pulmonary disorders, posterior reversible encephalopathy syndrome, gastrointestinal problems, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), tumor lysis syndrome (metabolic complications that may arise during cancer treatment), or liver disorders. Additionally, inform your doctor if you have diabetes, as this injection may influence your blood glucose levels.